Shield Therapeutics PLC (STX)

Industry Drug Manufacturers - Specialty & Generic
Sell

2.20p

Buy

2.50p

arrow-down-0.05p (-2.08%)

Prices updated at 16 May 2025, 14:50 BST
| Prices minimum 15 mins delay
|
Prices in GBX
Shield Therapeutics PLC is focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. It is a specialty pharmaceutical company.
FTSE All-Share
arrow-up0.59%
LSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Chairman
Mr. Peter Hermann William Llewellyn-Davies
CEO
-
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
63
Head office
Northern Design Centre
Newcastle
United Kingdom
NE8 3DF
mobile
+44 1915118500
letter
investorrelations@shieldtx.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Mr. Peter Hermann William Llewellyn-Davies
Non-Executive Director, Vice Chairman
-

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
Miton Asset Management Limited16,779,605
Premier Miton UK Smaller Companies16,779,605
Miton UK Microcap12,333,531
Intuitive Investments Group PLC-
FIL Investment Services (UK) Ltd-

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
13 Feb 2025Purchase
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.